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Differences in DNA Methylation and 
Functional Expression in Lactase 
Persistent and Non-persistent 
Individuals
Milena N. Leseva1, Richard J. Grand2, Hagen Klett3,4,5, Melanie Boerries3,4,5, Hauke Busch  3,8, 
Alexandra M. Binder6 & Karin B. Michels1,6,7
In humans the expression of lactase changes during post-natal development, leading to phenotypes 
known as lactase persistence and non-persistence. Polymorphisms within the lactase gene (LCT) 
enhancer, in particular the −13910C > T, but also others, are linked to these phenotypes. We were 
interested in identifying dynamic mediators of LCT regulation, beyond the genotype at −13910C > T. 
To this end, we investigated two levels of lactase regulation in human intestinal samples obtained 
from New England children and adolescents of mixed European ancestry: differential expression 
of transcriptional regulators of LCT, and variations in DNA methylation, and their relation to 
phenotype. Variations in expression of CDX2, POU2F1, GATA4, GATA6, and HNF1α did not correlate 
with phenotype. However, an epigenome-wide approach using the Illumina Infinium HM450 bead 
chip identified a differentially methylated position in the LCT promoter where methylation levels 
are associated with the genotype at −13910C > T, the persistence/non-persistence phenotype and 
lactase enzymatic activity. DNA methylation levels at this promoter site and CpGs in the LCT enhancer 
are associated with genotype. Indeed, taken together they have a higher power to predict lactase 
phenotypes than the genotype alone.
Lactase non-persistence, also known as adult-type hypolactasia, is the molecular basis of the inability to hydrolyze 
the lactose found in milk1,2. In most mammals, physiological down-regulation of the lactase gene (LCT) occurs 
around the time of weaning and results in low lactase activity throughout adult life2,3. The molecular mecha-
nisms of this early life switch from lactose tolerant-to-intolerant phenotype are not completely understood. While 
lactase does not persist in the majority of the human population, certain ethnic groups have undergone an evolu-
tionary adaptation allowing them to digest lactose even in adulthood4,5. However, the molecular underpinnings 
of this sustained lactase gene expression continue to be only partially explained.
On one hand, genetic variations may play a regulatory role. In Northern Europeans, for example, the T-allele 
of the −13910C > T intronic variant (rs4988235) located 13,910 bps upstream of the LCT transcription start site 
has been associated with the trait of lactase persistence6,7. On the other hand, although it is generally accepted that 
there is a strong association between the ancestral -13910*C allele with lactase non-persistence and the variant 
-13910*T allele with lactase persistence in people of European descent, in some cases these genotypes are not 
completely predictive of the phenotype8. Yet, the physiological change in lactase gene expression occurs in the 
context of a stable DNA sequence. This suggests the presence of dynamic mediators of LCT regulation such as 
epigenetic modifications and/or transcriptional changes.
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The small intestine absorbs molecules from the intestinal lumen through enterocytes, the predominant 
cell type of the intestinal columnar epithelium that possess microvilli to increase surface area for digestion. 
Microvillous enzymes hydrolyze oligo- and disaccharides to monosaccharides9, among them lactose, the disac-
charide found in milk, which is hydrolyzed by the apical membrane-anchored glycoprotein known as lactase 
phlorizin hydrolase (LPH). The different cell types of the intestine are replenished through continuous differen-
tiation of intestinal stem cells (ISCs) in the crypt. The extent of DNA methylation dynamics during this process 
in humans and during postnatal intestinal maturation is largely unknown, because of inaccessibility of tissue 
over different time points. It is only recently that the role of DNA methylation changes during the development 
from fetal to pediatric intestinal epithelium, and their association with disease, has begun to be understood10. 
In the context of mouse intestinal development, Dnmt1-mediated maintenance of methylation has been shown 
to be essential for crypt ISC differentiation11–13. Indeed, genes such as mouse lactase (Lct) are induced upon dif-
ferentiation to enterocytes, with a corresponding decrease in DNA methylation at specific CpG sites11. Dnmt1 
is also required during mouse intestinal maturation postnatally14. Because of the high degree of conservation in 
expression patterns and regulatory mechanisms, it was feasible that DNA methylation also plays an important 
role in regulation of human LCT. This was confirmed by Labrie et al. who identified epigenetically controlled reg-
ulatory elements where differential DNA methylation accounted for inter-individual differences of lactase mRNA 
level in a Lithuanian cohort of individuals15. In that study, microarray-based interrogation of DNA modifications 
across human chromosome 2 and subsequent targeted bisulfite padlock-probe sequencing of the genomic region 
encompassing LCT were used to identify a total of 35 CpGs, clustered in 7 regions where enterocyte-specific DNA 
methylation differences could be detected. Two of these, namely MCM6 intron 13 (where rs4988235 resides) 
and MCM6 exon 16, were shown to be differentially methylated in CC vs. C/T vs. TT individuals. While the 
authors were able to demonstrate genotype-dependent changes in DNA methylation and an association between 
methylation variation and lactase mRNA levels, their analysis did not take into account LPH enzymatic activity 
levels in designation of the lactase persistence/non-persistence phenotypes. To our knowledge, although lactase 
enzyme activity and LCT mRNA expression levels are highly correlated, there is no known established cut-point 
for lactase gene expression in determination of persistence vs. non-persistence.
Recently, Baffour-Awuah et al. have investigated the association between the genotype at rs4988235 and phe-
notypic markers such as LCT mRNA expression and LPH enzymatic activity in a heterogeneous cohort of chil-
dren and adolescents mostly of European ancestry8. Here, we used a subset of samples from this cohort to identify 
additional levels of lactase regulation contributing to the switch from lactase persistence to non-persistence that 
occurs early on in life. We have chosen a method for analysis of DNA methylation that is commonly used in 
epigenome-wide association studies and provides the opportunity for discovery of differentially methylated posi-
tions16,17. Through regression modeling we show that DNA methylation in the enhancer and promoter site of the 
LCT gene, rather than differential regulation of intestinal transcription factors, e.g. CDX2, POU2F1, GATA4/6 or 
HNF1α, is predictive of lactase persistence/non-persistence. Although not the first investigation of DNA methyl-
ation as a molecular mechanism for the regulation of LCT expression15, we have performed the first genome-wide 
DNA methylation profiling using intestinal tissues obtained from children and adolescents, with the youngest 
being 8 years old.
Results
RT-qPCR analysis of intestinal transcription factors reveals no differential expression in lactase 
persistent vs. non-persistent individuals. Based on their importance for LCT gene regulation, we inves-
tigated differential expression of the transcription factors (TFs) GATA4, GATA6, HNF1α and CDX2 between 
lactase persistent and non-persistent individuals. We further included POU2F1 (also known as OCT1) as it binds 
preferentially to the rs4988235 T-allele, thereby stimulating expression from the LCT promoter18. We quanti-
fied the TF expression from n = 79 tissue biopsies using RT-qPCR, wherein we defined lactase persistence and 
non-persistence based on lactase enzymatic activity being greater or less than 15 U/g protein, respectively1,8. 
Among lactase persistent individuals, the median enzymatic activity was approximately 32 U/g protein, ranging 
from the cut-off of 15 U/g to 73.7 U/g protein (Supplementary Figure S1a).
We observed moderate to strong positive Spearman correlations among transcription factor mRNA levels 
ranging from ρ = 0.44 to 0.60 (p < 0.05; Fig. 1A), which is not surprising given that the above TFs are essential for 
gut development and intestinal stem cell differentiation19–24. The strongest correlations were observed between 
CDX2, POU2F1, and GATA6. Weaker, yet significant associations were observed between GATA4 and CDX2, 
as well as between GATA4 and HNF1α expression levels (ρ = 0.24 and ρ = 0.26, respectively). Interestingly, 
CDX2 expression levels were associated with genotype, being significantly lower in TT homozygous individuals 
(p = 0.022; Fig. 1B). None of the other TFs were associated with ethnicity, gender, age, genotype, lactase mRNA 
expression or lactase persistence/non-persistence status (Fig. 1C). However, increased lactase enzymatic activity 
was significantly associated with higher levels of GATA4 expression (p = 0.01; Fig. 1D), after adjusting for gender 
and age. Although speculative, one explanation for this result might be that GATA4 could potentially act as a 
positive regulator of genes important for LPH processing and activation, however, the identity of such putative 
GATA4-targeted genes currently remains elusive. As expected, LCT gene expression in the healthy human intes-
tine is unlikely to depend on the above TFs alone, confirming that the level of transcription factor expression 
cannot explain inter-individual variation in LCT expression. Neither is lactase persistence nor non-persistence 
associated with TF expression levels, which must therefore depend on additional regulators.
Genome-wide DNA methylation analysis reveals differentially methylated positions (DMPs). 
The genotype at −13910C > T (CC or TT) is a strong predictor of the lactase persistence/non-persistence phe-
notype (p = 0.0001, Chi-squared test). However, its predictive power for the prevalent mixed C/T genotype in 
this cohort is weak (p = 0.5). Thus, we decided to investigate the epigenetic contribution to LCT regulation and 
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Figure 1. RT-qPCR analysis for major intestinal transcription factors (TF) in lactase persistent and non-
persistent individuals. (A) Spearman correlation coefficients (upper triangle) and scatter plots (lower triangle) 
between relative expression levels of CDX2, GATA4/6, POU2F1 and HNF1α. The intensity of color corresponds 
to the relative strength of the associations (*p < 0.05; **p < 0.001). (B) Relative expression of transcription 
factors CDX2, GATA4/6, POU2F1 and HNF1α in individuals belonging to CC, C/T or TT genotypes at 
rs4988235 normalized to beta-ACTIN and GAPDH. (C) Relative expression of transcription factors CDX2, 
GATA4/6, POU2F1 and HNF1α in lactase persistent and non-persistent individuals. (D) Association between 
TF expression and disaccharidase enzymatic activity (enzymatic activity data from Baffour-Awuah et al.8).
www.nature.com/scientificreports/
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potential association with adult-type hypolactasia as an additional regulatory mechanism beyond the genome and 
intestinal TF expression levels.
While epigenetic mechanisms facilitate phenotype without a corresponding change in DNA sequence, their 
contribution to LCT regulation in the human intestine has been explored by only one study to date, which 
focused on a 100 kb region surrounding the LCT and MCM6 genes15; accordingly, we analyzed genome-wide 
DNA methylation in a subset of patients (n = 60), half of which were phenotypically lactase persistent, and half 
non-persistent according to the clinical definition described previously1,8. The patients belonged to the three 
possible genotypes at rs4988235: homozygous CC (n = 13), homozygous TT (n = 15), and heterozygous C/T 
(n = 32). The sample characteristics are summarized in Fig. 2A. Interestingly, only 3 patients (all CC genotype) 
had self-reported lactose intolerance. An explanation for this is that chronic ingestion of milk will induce lac-
tose fermenting colonic microflora, thereby ameliorating symptoms of gastrointestinal discomfort. To investigate 
whether or not the lactase persistent phenotype or rs4988235 genotype are associated with epigenetic differences, 
we performed a genome-wide DNA methylation analysis using the Illumina Infinium HM450 bead chip. We 
excluded 6 patients due to low sucrase activity ≤20U/g from all further phenotype analysis25. To control for tech-
nical variation within the chip analysis we performed two patient sample replicates. Additional characteristics of 
patients included in the DNA methylation analysis are summarized in Table 1. It should be emphasized that most 
of the individuals in this heterogeneous cohort are of European ancestry, however, there are some with African, 
Asian or mixed descent. Detailed ancestry information for each subject can be found in Supplementary Table 1.
We are not aware of any clinical feature that might be responsible for the lactase non-persistence phenotype 
of the three TT individuals (see Table 1). It should be noted that these non-persistent TT individuals have an 
average sucrase enzymatic activity level that is lower than the average for the persistent TT individuals (33.7 U/g 
and 56.3 U/g, respectively). However, the average S/L ratio was 2.9 for the non-persistent TT’s and 1.69 for the 
persistent TT’s, respectively. In addition, there was a recent study by Goodrich et al. which suggested an associa-
tion between gut Bifidobacterium content and the lactase gene locus, and might also help explain the discrepancy 
between phenotype and genotype observed for these non-persistent TT individuals26.
Figure 2. Genome-wide DNA methylation analysis of lactase persistent and non-persistent individuals. 
(A) Composition of samples included on the 450K DNA methylation array. The number of samples in each 
group, non-persistent (NON-PER) and persistent (PER), is given according to their genotype at −13910C > T 
(rs4988235). (B) Outlier prediction following background correction, dye-bias normalization and filtering: all 
probes with a detection value p > 0.01 in at least 10% of the data; probes with bead count ≤ 3; and probes with 
known SNPs. (C) PCA plot of DNA methylation variation at all CpGs, excluding CpGs on sex chromosomes 
(X and Y) after batch correction using ComBat. (D–E) Colorspace corresponds to methylation levels as z-score 
transformed M-values (yellow = hypo-, blue = hypermethylation). (D) Top 20 DMPs identified following 
ordinal regression of genotype (CC = 0, C/T = 1, TT = 2); (E) Top 20 DMPs identified from ordinal regression 
analysis using quartiles of enzymatic activity levels (q1 = [0, 6.8], q2 = [6.8, 14.8], q3 = [14.8, 28.6], q4 = [28.6, 
73.7]). Both analyses were adjusted for sex, age and estimated surrogate variables. Nearest gene of the DMPs is 
displayed in parenthesis. A *designates the three self-reported lactose-intolerant individuals (all CC genotype).
www.nature.com/scientificreports/
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Following background correction and data normalization, two samples were identified as outliers and 
removed from further analysis based on the median methylated and unmethylated intensities (Fig. 2B, labeled 
in red). Although all samples entered the Infinium data production pipeline as a single batch and were run in 
parallel, principal component analysis (PCA; excluding CpGs on the X- and Y-chromosomes) did reveal batch 
effects across the lanes of the Illumina 450K chip that can be seen from the deviation of technical replicates 
(Supplementary Figure S2). Therefore M-values were adjusted using ComBat27. While PCA analysis on corrected 
M-values did not reveal any phenotypic or genotypic clustering, batch effects were efficiently removed (Fig. 2C).
We used Surrogate Variable Analysis (SVA) to control for any unmodeled sources of DNA methylation het-
erogeneity. When estimating the number of surrogate variables, we identified 12 corresponding to the number 
of confounding factors. Adjusting for these factors and modeling the possible genotypes at −13910C > T as an 
ordinal covariate according to the number of T-alleles (i.e. CC = 0, C/T = 1, TT = 2) revealed cg20242066 among 
the 20 top-ranked DMPs (ranked 10th; Fig. 2D). Furthermore, cg20242066 was among the 20 top-ranked DMPs 
(ranked 5th) when testing the association with LPH activity using quartiles of enzymatic activity levels (q1 = [0, 
6.8], q2 = [6.8, 14.8], q3 = [14.8, 28.6], q4 = [28.6, 73.7]) and controlling for 12 sources of potential bias, as sug-
gested by the SVA (Fig. 2E). In order to account for inter-sample differences in sucrase enzymatic activity levels, 
we also adjusted for sucrase in the linear model. This did not dramatically change the top DMP hits identified 
from the 450K methylation array with cg20242066 now ranked 13th for the genotype analysis (Supplementary 
Figure S3a) and 3rd for phenotype (LPH enzymatic activity; Supplementary Figure S3b).
Cg20242066 is located approximately 500 bps upstream of LCT within the proximal promoter region 
(Fig. 3A). We additionally verified the results from the Illumina bead chip by pyrosequencing at cg20242066. 
In agreement with the methylation array, sequencing found the cg20242066 site to be differentially methylated 
in CC vs. C/T vs. TT individuals and lactase persistent vs. non-persistent individuals (Fig. 3B,C). Kendall’s Tau 
correlation coefficients suggested a negative correlation of the methylation at cg20242066 with both the geno-
type (correlation = −0.40, p = 0.00018) and the phenotype according to clinical definition (correlation = −0.36; 
p = 0.0016). We further detected significant negative correlations between methylation and the lactase enzymatic 
activity (correlation = −0.40 p = 7.75E-05; Fig. 3D), and between methylation and LCT gene expression (corre-
lation = −0.42, p = 2.5E-05; Fig. 3E). The pyrosequencing assay covered an additional CpG next to cg20242066 
(see Supplementary Table 2), however, it did not appear to be differentially methylated in CC vs. C/T vs. TT indi-
viduals, or in persistent vs. non-persistent individuals. Taken together, these results suggest a strong association of 
methylation at cg20242066 with the −13910C > T genotype and thus the persistence/non-persistence phenotype.
LCT enhancer methylation levels are associated with genotype and phenotype. Given these genotype 
and phenotype associations with methylation at a locus in close proximity to LCT (cg20242066), we explored 
the potential impact of methylation of other regulatory elements associated with the LCT gene. We noted an 
additional association with genotype on the MCM6 gene (cg13056269), however it lost statistical significance 
after SVA adjustment and we did not investigate it further (Fig. 2D). We used pyrosequencing to investigate DNA 
methylation at three CpGs within the LCT enhancer region upstream of rs4988235 (chr2:136608680-136608822, 
hg19; Fig. 4A) additional to the Illumina bead chip. This region corresponds to intron 13 of the MCM6 gene, 
where multiple SNPs, all within a few hundred base pairs of each other, have been described not only in lactose 
tolerant Europeans, but also in lactase persistent pastoralist populations of Africa and the Middle East4,28,29. This 
region also overlaps with the human MCM6 intron13-exon13 region where Labrie et al. previously identified 
inter-individual and cell-type specific variation of LCT mRNA levels associated with DNA modification levels15.
The average DNA methylation levels across these CpGs were significantly higher in CC vs. C/T vs. TT indi-
viduals and in non-persistent individuals vs. persistent (Fig. 4B,C). This effect of genotype at rs4988235 on DNA 
methylation variation within this region is similar to what has been previously reported for enterocytes15. As was 
the case for methylation levels on the LCT promoter, Kendall’s Tau correlation coefficients suggested a negative 
correlation between the LCT enhancer methylation and both the rs4988235 genotype and phenotype (correla-
tion = −0.65; p = 9E-10 and correlation = −0.45; p = 5E-5, respectively). We also observed a negative correlation 
Characteristic
Lactase Persistent 
(N = 30)
Lactase Non-
persistent (N = 30)
Average age 15.1 yrs 14.03 yrs
Ethnicity
 European ancestry n = 24 n = 23
 Other n = 6 n = 7
Gender
 Female n = 13 n = 17
 Male n = 17 n = 13
Genotype −13910C > T (rs4988235)
 CC n = 0 n = 13
 C/T n = 18 n = 14
 TT n = 12 n = 3
Table 1. Characteristics of study population used in DNA methylation analysis by Infinium 450K methylation 
microarray and Pyrosequencing including outlier samples.
www.nature.com/scientificreports/
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between methylation and LPH enzymatic activity (correlation = −0.48; p = 1.09E-6; Fig. 4D), and between 
methylation and LCT gene expression (correlation = −0.42; p = 2.08E-05; Fig. 4E). Of note, despite the similar 
correlation behavior of methylation levels at the LCT promoter and enhancer we only observed a weaker, albeit 
significant, positive correlation between the two (correlation = 0.26, p = 0.006; Fig. 5B).
The association between DNA methylation at the lactase enhancer and lactase enzymatic activity 
is largely attributable to the −13910C > T genotype. Previous studies have demonstrated that 
the genotype at −13910C > T (rs4988235) is associated with differential lactase enzymatic activity. The CC 
homozygous individuals generally have low enzymatic activity, while TT homozygotes have high enzymatic 
activity levels. The C/T heterozygotes in this cohort mostly have intermediate values but these are heteroge-
neous (Fig. 5A; enzymatic activity data from Baffour-Awuah et al.)8. As DNA methylation variation is affected 
by genetic variation, we designed three linear models to test the association between DNA methylation at the 
lactase enhancer site and lactase enzymatic activity under the influence of the genotype at rs4988235. We fitted 
the DNA methylation obtained from pyrosequencing individually to (i) lactase enzymatic activity or (ii) the 
genotype and (iii) the combination of them, while adjusting all models for age and gender. Both the genotype 
and enzymatic activity are highly predictive for the DNA methylation (p < 0.001), with the former being more 
predictive than the latter having R2 values of 0.64 and 0.31, respectively (see Table 2 for model fit results). A 
full linear model combining the two predictors revealed only the rs4988235 genotype as significant (p < 0.001, 
adj. R2 = 0.65). Comparing the full to the reduced linear models showed a significant improvement only for 
lactase enzymatic activity (ANOVA; p < 0.001), but no improvement for genotype (ANOVA; p > 0.1). These 
results suggest that most of the DNA methylation variation at the LCT enhancer is explained by the genotype 
at rs4988235 alone.
We performed the same analysis for DNA methylation at cg20242066. In this scenario the genotype again was 
a significant predictor in both the partial and the full model, whereas lactase enzymatic activity was only signifi-
cant in the partial model (Table 2). Testing the reduced versus the full model by ANOVA showed no improvement 
with respect to the genotype (ANOVA; p > 0.1), but a significant improvement for lactase enzymatic activity 
(ANOVA; p < 0.01). This confirms again the influence of the rs4988235 genotype on DNA methylation variation.
Figure 3. Pyrosequencing of DNA methylation at cg20242066. (A) Schematic of LCT proximal promoter with 
location of cg20242066 upstream of the first three exons of the gene. The genomic coordinate of cg20242066 
is also given (genome build hg19). (B) DNA methylation quantification in CC vs. C/T vs. TT individuals, as 
well as in (C) Phenotypically Persistent (PER) and Non-persistent (NON-PER) individuals. Student’s T-test 
was calculated for inter-group comparisons (*p < 0.05; **p < 0.001). Number of individuals in each group is 
given in parenthesis. (D) Correlation between DNA methylation at cg20242066 and lactase enzymatic activity 
(enzymatic activity data from Baffour-Awuah et al.8). (E) Correlation between DNA methylation at cg20242066 
and LCT gene expression (LCT gene expression data from Baffour-Awuah et al.8).
www.nature.com/scientificreports/
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Figure 4. Pyrosequencing of DNA methylation at the LCT enhancer. (A) Schematic of LCT enhancer with 
location of the three CpGs under investigation. The position of −13910C > T (rs4988235) in relation to the 
CpGs and the genomic coordinates of the PCR product are also given. (B) DNA methylation quantification in 
CC vs. C/T vs. TT individuals, as well as in (C) Phenotypically Persistent (PER) and Non-persistent (NON-
PER) individuals. Student’s T-test was calculated for inter-group comparisons (*p < 0.05; **p < 0.001). Number 
of individuals in each group is given in parenthesis. (D) Correlation between DNA methylation averaged 
over the three CpGs and lactase enzymatic activity (enzymatic activity data from Baffour-Awuah et al.8). (E) 
Correlation between DNA methylation averaged over the three CpGs and LCT gene expression (LCT gene 
expression data from Baffour-Awuah et al.8).
Figure 5. Correlation between DNA methylation at the LCT enhancer and cg20242066. (A) Lactase enzymatic 
activity according to the genotype of the individual at −13910C > T (rs4988235). Student’s T-test was calculated 
for inter-group comparisons (*p < 0.05; **p < 0.001). (B) Correlation between DNA methylation at the LCT 
promoter cg20242066 and LCT enhancer.
www.nature.com/scientificreports/
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Phenotype prediction with DNA methylation on the lactase enhancer/promoter and the rs4988235 
genotype. Finally, we investigated the predictive ability of DNA methylation and genotype for clinical lactase 
persistence/non-persistence phenotype, and continuous enzymatic activity levels. Apart from the patients with 
low sucrase activity levels, we further excluded one outlier with high lactase enzymatic activity of 73.7 U/g pro-
tein from analysis. As potential predictors we used pyrosequencing methylation levels for the LCT enhancer 
and promoter, the −13910C > T genotype (CC, C/T and TT) as well as combinations of the three, which 
resulted in seven different sets of predictors (Table 3). To evaluate the prediction performance, we conducted a 
leave-one-out-cross-validation (LOOCV), i.e. using all patients but one for training and predicting the patient 
that was left out iteratively for all patients. To predict continuous enzymatic activity levels, we used a linear regres-
sion model and evaluated performance according to the cross-validated coefficient of variation R2 between pre-
dicted and true values. In case of lactase persistence/non-persistence, we used a logistic regression function to 
predict the bivariate response variable and evaluated the model performance from the receiver-operating charac-
teristic (ROC). The best predictions for both the enzymatic activity levels (R2 = 0.36) and the phenotypic bivariate 
response (AUC = 0.81) were obtained from combining the methylation status of the LCT promoter and enhancer 
as depicted in Fig. 6A,B, respectively (Table 3). Quite surprisingly, the methylation levels of the LCT promoter and 
enhancer outperform the predictive power of the rs4988235 genotype (R2 = 0.24, AUC = 0.65) or genotype/meth-
ylation combination (R2 = 0.29, AUC = 0.80) for the continuous or bivariate readout. Thus, methylation must play 
an important and direct role in determining the LCT gene expression and lactase activity, and can predict the 
persistence/non-persistence phenotype, especially for the heterogeneous mixed C/T genotype.
Discussion
In this study, we have investigated molecular mechanisms at the transcriptional and epigenome level that might 
control LCT expression, and maintain decreased levels of jejunal lactase throughout adulthood in the majority 
of the human population. Human LCT is activated in the fetal intestine late in embryonic development and 
reaches peak expression at 40 weeks gestation30. Physiological down-regulation of lactase expression in humans 
occurs post-weaning in the absence of intestinal injury or disease. Furthermore, lactase phlorizin hydrolase is not 
affected by dietary changes and lactose intake. LPH is not reduced by the absence of lactose in the diet31; neither 
does lactose feeding induce lactase enzymatic activity and gene expression32.
It is accepted that lactase gene expression is primarily regulated at the transcriptional level33–35, and in 
non-human mammals Cdx2, Gata4/6 and Hnf1α TFs collectively activate this gene. However, we did not observe 
any of these to be differentially expressed in intestinal biopsies from lactase persistent and non-persistent individ-
uals. The −13910C > T variant (rs4988235) has previously been shown to be associated with lactase persistence in 
people of European ancestry, the T-allele being responsible for functional persistence of the lactase promoter7,18. 
Notably, when we stratified our cohort according to genotype at rs4988235, CDX2 expression was lower in TT 
CpG location Linear model
Enzymatic 
activity C/T TT Sex Age Adjusted R2
LCT enhancer
Enzymatic activity −0.40*** — — −5.27 0.62 0.31
Genotype — −18.04*** −27.88*** −3.59 0.34 0.64
Full −0.11 −16.3*** −25.1*** −3.45 0.38 0.65
LCT promoter
Enzymatic activity −0.11** — — 1.00 0.14 0.14
Genotype — −3.54** −6.19*** 1.26 0.07 0.25
Full −0.04 −2.80* −5.03** 1.32 0.09 0.26
Table 2. Linear regression analysis of pyrosequencing measurements, LPH enzymatic activity and/or 
the −13910C > T genotype. Asterisks indicate significance of coefficients (p < 0.1, *p < 0.05, **p < 0.01, 
***p < 0.001). The table shows the predictive power of DNA methylation for all −13910C > T genotypes. The 
coefficients for C/T and TT are reported with respect to the CC genotype. Negative coefficients indicate lower 
methylation levels for the C/T and TT genotype compared to the CC genotype.
Set Predictors
R2 true vs. predicted 
enzymatic activity levels
AUC of lactase persistence/
non-persistence prediction
Set1 Genotype 0.24 0.65
Set2 LCTenhancer (Methylation) 0.30 0.79
Set3 LCTpromoter (Methylation) 0.15 0.73
Set4 Genotype + LCTenhancer 0.26 0.65
Set5 Genotype + LCTpromoter 0.24 0.81
Set6 LCTenhancer + LCTpromoter 0.36 0.81
Set7 Genotype + LCTenhancer + LCTpromoter 0.29 0.80
Table 3. Prediction performances for enzymatic activity levels and lactase persistence/non-persistence 
phenotype using different sets of predictors: LCT enhancer and promoter are averaged methylation levels in 
their respective location based on DNA methylation measurements from pyrosequencing. The −13910C > T 
genotype consists of categories CC, C/T and TT.
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homozygotes. In addition, we found an increase in GATA4 expression to be associated with LPH enzymatic 
activity, although we did not observe an association between GATA4 expression and lactase gene expression 
levels. As we did not observe differential TF regulation, post-translational processing and complex glycosylation 
of the protein that LCT codes for should influence lactase abundance and enzymatic activity36–38. The association 
between GATA4 expression level and LPH enzymatic activity, therefore, might be rather through regulation of 
genes important for LPH post-translational modification and activation.
Using an unbiased epigenome-wide approach verified by targeted pyrosequencing, we have identified posi-
tion cg20242066 (chr2: 136595261; hg19) as differentially methylated in the jejunum of lactase persistent and 
lactase non-persistent children and adolescents. This CpG is located in the region essential for spatio-temporal 
regulation of human LCT expression, which has been previously demonstrated by introducing a construct con-
taining the sequence 3.3kbs upstream of the TSS in transgenic mice39. Linear regression analysis showed that 
DNA methylation at both the LCT promoter and enhancer is largely impacted by genotype at −13910C > T, 
with CC homozygotes having the highest, and TT homozygous individuals the lowest methylation levels. Most 
importantly, however, cross-validation analysis revealed that methylation at the LCT promoter and enhancer was 
highly predictive of lactase enzymatic activity, and the persistence/non-persistence phenotype. The predictive 
power outperformed the hitherto existing genotype at rs4988235, which fails prediction for the C/T genotype. 
Hence, promoter and enhancer methylation might be a valuable biomarker for phenotype prediction. This reflects 
the existing crosstalk between DNA methylation and genetic variation, which has been reported previously in 
population studies40–42. Indeed, DNA methylation patterns associated with specific genotypes (i.e. meQTLs) have 
consistently been shown to influence gene expression and disease phenotypes43–45. Interestingly, a recent study 
by Banovich et al. in lymphoblastoid cell lines demonstrated that SNPs, which affect transcription factor bind-
ing affinities are associated with DNA methylation at CpGs in proximity46. In that study it was suggested that 
changes in TF binding are an early regulatory step leading to subsequent molecular changes, including epigenetic. 
Differential binding of POU2F1, preferentially to the -13910*T-allele, which is associated with lactase persis-
tence18 might be acting in much the same way. Within the highly conserved lactase TATA-box promoter a dif-
ferentially methylated position, such as cg20242066, might function to preferentially recruit regulatory proteins. 
However, no major intestinal transcription factor consensus sequences appear to be close to this CpG.
Prior to SVA adjustment our list of top 20 DMPs associated with genotype revealed cg13056269 
(chr2:136633607; hg19), a CpG site located in intron 1 of the upstream MCM6 gene. In the future, it would be 
interesting to investigate whether intron 1 of MCM6 might also affect LCT gene expression, as does intron 13 of 
the same gene where −13910C > T (rs4988235) and the LCT enhancer are located.
It is important to mention that cg20242066 was not identified as differentially methylated by Labrie et al. 
(see their Supplementary Table 1)15. The authors of that study used a library-free version of BSPP (bisulfite 
padlock-probe sequencing)47, which allows interrogation of DNA methylation at single nucleotide resolution, but 
is limited by the position and efficiency of the probes that can be designed. The efficiency of the probes depends 
on the underlying target sequence, including its CG content and length48. A search in the list of human probes 
used in Labrie et al. did not reveal the CpG that we report on here.
Figure 6. Testing the performance of LCT promoter and enhancer methylation in predicting lactase enzymatic 
activity levels and the bivariate phenotype lactase persistence/non-persistence. (A) Power of combined LCT 
promoter and enhancer methylation to predict lactase enzymatic activity levels. (B) Plot of Area under the curve 
(AUC) of the receiver-operating characteristic (ROC) calculated using genotype at −13910C > T (rs4988235), 
LCT promoter and enhancer DNA methylation, and combinations thereof (shown in detail in Table 3). Perfect 
prediction corresponds to AUC = 1; random prediction corresponds to AUC = 0.5. Set 1 uses rs4988235 
genotype alone, while Set 6 the combination of LCT promoter and enhancer methylation to distinguish lactase 
persistors from non-persistors. In plots A. and B. one outlier with lactase enzymatic activity at 73.7 U/g was 
excluded from the analysis. Enzymatic activity data is from Baffour-Awuah et al.8.
www.nature.com/scientificreports/
1 0SCIENTIFIC RepoRts |  (2018) 8:5649  | DOI:10.1038/s41598-018-23957-4
In summary, we have investigated the contribution of epigenetics to the lactase persistence/non-persistence 
phenotypes, including lactase gene expression and enzymatic activity. We have identified putative lactase 
meQTLs, which are differentially methylated between lactase persistent and lactase non-persistent individuals. 
In genetically homogenous populations, it appears that the T-allele at −13910C > T might be dominant leading 
to a trimodal distribution in lactase enzymatic activities and the complete correlation of lactase persistence with 
the presence of the variant allele. However, in genetically heterogeneous populations, such as the one discussed 
here, we observe that this likely is not the case. Methylation at the LCT enhancer and the LCT promoter are 
both affected by the genotype at rs4988235, and appear to be continuously associated with lactase phenotypes. 
Combining them outperforms the previously known genotype when it comes to predicting the lactase persistence 
vs. lactase non-persistence phenotype and the lactase enzymatic activity levels. Despite the fact that we have 
attempted to remove any unwanted sources of inter-sample variation, we cannot entirely exclude the possibility 
that such variation exists and has remained unaccounted for even after surrogate variable analysis. Our observa-
tion of a closer correlation of DNA methylation with phenotype (as assessed by enzyme activity), than correlation 
of genotype with enzyme activity, could theoretically be a reflection of that variation, irrespective of the fact that 
the biopsies were deemed normal by histology. However, as Labrie et al. have previously described15, the regions 
surrounding the LCT gene where DNA methylation variation associated with lactase persistence/non-persistence 
was detected, overlap with DNaseI hypersensitivity sites, which carry histone marks of active enhancers. Hence, 
DNA methylation levels at the LCT enhancer and promoter are reflective of additional layers of epigenetic regu-
lation, which might explain their improved performance in prediction of lactase phenotypes.
Materials and Methods
Study population. Mucosal pinch-biopsy samples were obtained from the third portion of the duodenum in 
patients (ages 8 to 23 years) undergoing diagnostic esophago-gastroduodenoscopy at Boston Children’s Hospital 
between 2005 and 2007 as described in detail by Baffour-Awuah et al.8. Indications for endoscopy included dys-
phagia, chronic abdominal pain, symptoms of gastroesophageal reflux and esophagitis. Patients with known 
small intestinal disorders such as celiac disease, diarrhea or other pathological conditions, such as gastrointesti-
nal bleeding, inflammatory bowel disease, or immunodeficiency were excluded. Signed informed consent/assent 
was obtained from each patient and his/her parent or legal guardian who agreed to participate in the initial, and 
any follow-up, studies. The samples were snap-frozen and stored at −80 °C. Two biopsy samples were submitted 
for histological analysis; one biopsy was saved for total protein and disaccharidase assays, and the other samples 
were available for RNA and DNA analysis, as reported (Baffour-Awuah et al.), and epigenetic assays as described 
below. Permission to use a subset of these samples (aged 8 to 19) for the study of epigenetic regulation of lactase 
was granted following review by Partners Human Research IRB Committee at Brigham and Women’s Hospital 
in Boston and the Committee on Clinical Investigation at Boston Children’s Hospital in Massachusetts, USA. All 
experiments were performed in accordance with relevant guidelines and regulations, including the removal of 
any identifying information.
Examination of biopsies by two experienced GI pathologists revealed normal villus height and crypt depth, 
and normal cellular distribution, with an absence of intraepithelial lymphocytes or abnormal inflammatory 
cells in the lamina propria. Standards for morphological assessment of intestinal biopsies have been previously 
published49.
Subjective reporting of lactose intolerance was obtained by history from each subject. Only 3 patients included 
in this study were lactose intolerant by report. Disaccharidase analysis were assayed in a CLIA certified labo-
ratory as originally reported8 using the method of Dahlqvist50. Quality control for disaccharidase assays at the 
Gastrointestinal Laboratory of the Buffalo Children’s Hospital (Kaleida Health; Buffalo, NY) is achieved using 
standard procedures. At least annually, masked, randomly selected, frozen samples are submitted to a reference 
laboratory where they are assayed in triplicate by the Dahlqvist method. Results are generally identical to the 
value originally obtained for that sample in the submitting laboratory (within only a 0.5% variation).
Ranges of disaccharidase activity, Sucrase/Lactase ratios and definitions of lactase persistence and 
non-persistence were similar to those in previously published studies1,51–53. Therefore, cut-point values of 
lactase < 15 U/g protein and S/L ratio > 2 was considered lactase non-persistence, while lactase activity > 15 U/g 
and S/L < 2 was considered lactase persistence. As published previously, lactase activity did not change with age 
in this sample population8.
DNA isolation. Genomic DNA was isolated using DNeasy Blood and Tissue Kit by QIAGEN (#69506). 
Briefly, a small tissue biopsy was incubated at 56 °C in 180 uL Lysis Buffer supplemented with 20 uL Proteinase 
K solution for 2 hrs, or until the tissue was completely dissolved. As per the manufacturer’s protocol, 200 uL AL 
Buffer was pre-mixed with 100% ethanol in 1:1 ratio and added to each sample. The samples were then loaded 
onto the supplied columns and washed. Each sample was eluted twice in a total volume of 150 uL Elution Buffer. 
DNA quantity and quality was measured on a NanoDrop 1000 Spectrophotometer.
Genome-wide DNA methylation analysis. Genome-wide profiling of DNA methylation was performed 
using the Infinium Human Methylation 450K BeadChip at the University of Southern California Norris 
Comprehensive Cancer Center Molecular Genomics Core Facility. This methylation microarray surveys the DNA 
methylation status of 482,421 CpGs in the human genome. It interrogates approximately 99% of RefSeq genes 
including promoter, 5′ and 3′ gene body regions, as well as CpG sites located outside of gene coding regions. The 
probes are located within 80% of core promoters, 94% of distal promoters and 97% of all gene bodies. Coverage is 
provided for 94% of all CpG islands and 93% of all CpG island shores in the human genome.
Briefly, 1 µg genomic DNA for each sample was treated with sodium bisulfite, recovered using the Zymo EZ 
DNA Methylation Kit (Zymo Research, Irvine, CA) according to the manufacturer’s specifications and eluted 
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in 18 uL volume. An aliquot (3 uL) was removed for MethyLight-based quality control testing of bisulfite con-
version completeness and the amount of bisulfite converted DNA available for the Infinium Methylation assay. 
All samples that passed the QC tests entered into the Infinium DNA methylation assay data production pipe-
line. Data processing was performed at the USC High Performance Computing Center (HPCC) using dedicated, 
Linux-based, high performance computational cluster and enterprise storage. After the chemistry steps, Bead 
Arrays were scanned and the raw signal intensities extracted from the *.IDAT files using the Bioconductor minfi 
(1.12.0) package. The intensities were corrected for background fluorescence followed by dye-bias normalization. 
The beta values were calculated as M/(M + U + 100) as recommended by Illumina, in which M and U refer to 
the (pre-processed) mean methylated and unmethylated probe signal intensities, respectively. M-values were 
calculated as logit transformed beta values. Measurements in which the fluorescent intensity was not statistically 
significantly above background signal in at least 10% of the samples (detection p value > 0.01) or with bead 
counts ≤ 3 were removed from the data set. In addition, probes that overlap with known SNPs as well as repetitive 
elements were masked prior to data analyses: specifically, all HM450 probes that overlapped with common SNPs 
with a minor allele frequency of greater than 1% (UCSC criteria) at the targeted CpG site, as well as probes with 
common SNPs (MAF >1%) within 10 bp of the targeted CpG site. HM450 probes that were within 15 bases of the 
CpG lying entirely within a repeat region were also masked prior to data analyses.
Statistical analysis of the 450K methylation array. Prior to statistical analysis, sample outliers were 
removed based on the median methylated and unmethylated intensities (Fig. 2B), and CpG sites located on the X- 
and Y-chromosomes were masked to reduce gender effects. For phenotypic analysis, samples with sucrase activity 
levels <20 U/g were further excluded. Due to variation of technical replicates, we performed batch correction 
on the 450K lanes using ComBat27. Statistical analysis was performed on M-values as proposed in Du et al.54. 
To identify differentially methylated positions between groups or continuous variables, F-tests were calculated 
adjusting for age and gender using the limma pipeline55. In addition, in order to account for sources of unmod-
eled DNA methylation heterogeneity, we used surrogate variable analysis (SVA) as originally described by Leek et 
al.56,57. Heatmaps show z-score transformed M-values and are ordered based on Euclidean distance and average 
clustering. Associations among methylation and covariates were measured using Kendall’s Tau correlation.
Multiple linear regression analysis. Linear regression models were evaluated using the lm function from 
the stats package, where two-tailed p-values for covariates were obtained from the t-statistic. The adjusted R2 was 
calculated according to Wherry formula and linear models were compared by ANOVA.
Prediction performance of enzymatic activity levels and bivariate phenotype. Prediction was 
evaluated using LOOCV with a linear regression model for continuous enzymatic activity levels and a logistic 
regression model for the bivariate phenotype (persistence/non-persistence). To rank performances we used the 
coefficient of variation R2 between predicted and true enzymatic activity levels as well as the AUC for the bivariate 
response. ROC curves and AUC were calculated using the ROCR package58. All analyses were performed using 
the statistical program language R59.
Bisulfite conversion of DNA for Pyrosequencing. Bisulfite conversion of DNA was carried out using 
the EZ-DNA Methylation Gold Kit by Zymo Research (#D5006). Briefly, 500–1000 ng of genomic DNA in 20 uL 
was incubated with 130uL conversion reagent at 98 °C/10 min, followed by incubation at 64 °C for 2.5 hrs. The 
samples were then passed through columns, desulphonated for 20 min, washed and eluted with 15 uL elution 
buffer. This bisulfite converted DNA was stored at −20 °C and used for downstream PCR reactions.
Pyrosequencing. Genotyping of rs4988235 (−13910C > T), analysis of DNA methylation at the LCT 
enhancer and verification of the 450K results were performed by pyrosequencing on a PyroMark Q24 instrument 
(QIAGEN). Primers for all pyrosequencing assays were designed using the PyroMark Assay Design software 2.0 
and purchased from Integrated DNA Technologies (IDT). All biotinylated primers were HPLC purified. Detailed 
information on the pyrosequencing assays and procedures is provided in Supplementary Table 2. Pyrosequencing 
was carried out according to the manufacturer’s instructions (QIAGEN). Briefly, biotin labeled PCR prod-
ucts were incubated with Streptavidin Sepharose High Performance Beads (#17–5113–01; GE Healthcare Life 
Sciences) in the presence of PyroMark Binding Buffer (#979006) for 5–10 min at room temperature and constant 
agitation. The beads were then captured by the vacuum tool of the PyroMark workstation and washed consec-
utively in 70% ethanol, PyroMark Denaturation Solution (#979007) and 1 × PyroMark Wash Buffer (#979008). 
The biotin-tagged single-strand DNA was released onto the wells of PyroMark Q24 plates (#979201, QIAGEN) 
containing the respective sequencing primer diluted to a final concentration of 300 mM in PyroMark Annealing 
Buffer (#979009). The plate was then incubated at 80 °C/2 min and allowed to cool to room temperature before 
being placed into the PyroMark Q24 instrument. Pyrosequencing was performed using nucleotides, enzyme 
and substrate solutions provided in PyroMark Gold Q24 Reagents (#970802, QIAGEN) which were loaded in a 
PyroMark Q24 Cartridge (#979201, QIAGEN).
Reverse-Transcription quantitative PCR. For quantitative RT-qPCR analysis we excluded samples with 
sucrase-isomaltase (SI) levels < 25 U/g protein, according to previously established guidelines25. Exon-intron 
boundary-spanning primers were designed using the Primer3 v.4.0 software and purchased from IDT. cDNA 
was synthesized from 1000 ng of total RNA using the High Capacity cDNA Reverse Transcription Kit (Life 
Technologies) and the provided random primers. Negative controls containing no reverse transcriptase were 
included. Each primer pair was optimized for robust and target-specific amplification. Following optimization, 
qPCR reactions were carried out in duplicate on 96-well plates using a Mastercycler ep Realplex instrument 
(Eppendorf). A detailed list of RT-qPCR primers and conditions can be found in Supplementary Table 3. Raw 
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fluorescence values were exported from the Realplex 2.0 software following each run. These were used to estab-
lish baseline fluorescence and to analyze the amplification curves with the LinRegPCR software60,61. Relative 
gene expression was quantified by normalization to two reference genes, GAPDH and ACTIN, using the model 
described in Pfaffl, Nucleic Acids Research62. We excluded samples that showed signs of inhibition of RT-qPCR 
during amplification of the reference genes. A pool of total RNA from adolescent male jejunum was used as a cali-
brator (H.jej.). The relative expression level of each target gene was calculated by taking into account the efficiency 
(E) of amplification, and the quantification cycle (Cq) deviation of the sample versus the calibrator, in comparison 
to the reference genes using the formula:
Relative expression TargetGene E
AvgRefGene E
Cq H jej Cq sample
GeoMean RefGene Cq H jej GeoMeanRefGene Cq sample
( ( ) ( ))
( ( ) ( ))=
. . −
. . −
Statistical analysis of RT-qPCR. Gene expression levels of all of the investigated genes were approximately 
normally distributed in our cohort (Supplementary Figure S1b). Co-expressions among the TFs were measured 
using Spearmans rank correlation. Correlations between TF expression and continuous phenotypes were assessed 
using Pearson correlations, whereas associations with dichotomous or polytomous variables were analyzed using 
a t-test or one-way ANOVA, respectively. Linear models were used to assess the impact of adjustment for gender 
and age on the associations between TF expression, and both enzymatic activity and LCT expression. Statistical 
analysis was performed using R version 3.2.1 and data was visualized using ggplot2.
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